Pharma Industry News

For Shire, more margin pressure plus fewer growth sparks make for underwhelming 2018

Written by David Miller

One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down. On Wednesday, the company said it was predicting $14.90 to $15.50 per share, a range that sits below the $15.94 Wall Street had been expecting. And that “initial 2018 outlook suggests EPS needs trimming,” Jefferies’ Peter Welford wrote in a note to clients.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]